Navigation Links
Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
Date:8/6/2010

MOUNTAIN VIEW, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that company Senior Vice President and Chief Financial Officer, August J. Moretti will present during the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference.  The Alexza presentation will be on Friday, August 13, 2010 at 10:40 am ET.  The presentation will be webcast from the Southampton Inn in Southampton, New York.

To access the presentation via the Web, please go to the Investor Relations tab at www.alexza.com or at https://www.veracast.com/webcasts/bas/specpharma2010/id10116040.cfm.  A replay of the webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, submitted a New Drug Application in December 2009, and has a Prescription Drug User Fee Act (PDUFA) goal date of October 11, 2010.  In February 2010, Alexza established a partnership with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 in the U.S. and Canada.  

Alexza recently announced that it plans to advance AZ-007 (Staccato zaleplon) into Phase 2 clinical development with the first Phase 2 clinical trial projected to begin in 1H 2011.  AZ-007 is being developed for the treatment of insomnia in patients who have difficulty falling asleep, including those patients who awake in the middle of the night and have difficulty falling back asleep. For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties.  Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs.  The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission.  Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
2. Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
3. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
4. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
5. Alexza Secures $25 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
6. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
7. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
8. Alexza Pharmaceuticals Files Shelf Registration Statement
9. Alexza to Announce 2010 First Quarter Financial Results on Monday, May 10, 2010
10. Alexza Reports 2009 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
11. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , Dec 5, 2016 Research ... Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease ... - Global Forecasts to 2021" report to their offering. ... , , ... USD 730.7 Million in 2021 from USD 574.8 Million in 2016, ...
(Date:12/5/2016)...   BIOTRONIK today announced the first patients ... the safety and feasibility of performing the minimally invasive ... BioMonitor 2 is an insertable cardiac remote monitor ... a patient,s skin to help physicians accurately detect and ... a leading cause of stroke and heart failure. BioMonitor ...
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior ... the Dallas area” Tuesday evening at the 26th Annual SMU Cox Dallas 100™ ... Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish ... take advantage of a cosmetic procedure known as Carbon Dioxide (C02) Fractional ... appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges ... brush properly to achieve optimal results. This important necessity inspired an inventor from Las ... a way to ensure that people break or avoid bad techniques of brushing the ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen ... Atlanta office, will speak at the American Conference Institute’s 21st Drug & Medical ... also a Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, ...
(Date:12/2/2016)... , ... December 02, 2016 , ... On Dec. 2, ... Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have made ... by going above and beyond the standard of care, demonstrating leadership within the MPN ...
Breaking Medicine News(10 mins):